POPE-2: Colchicine to prevent pericardial effusion after cardiac surgery

The incidence of asymptomatic pericardial effusion after cardiac surgery is high. The aim of this study was to evaluate whether colchicine would be able to reduce the volume of postoperative pericardial effusion. This multicenter, double-blind, placebo-controlled study, randomized 197 patients with high risk of cardiac tamponade determined by the presence of persistent pericardial effusion from moderate to severe for more than 7 days after surgery using 1 mg colchicine versus placebo. At 14 days after randomization, no difference was observed in the volume of effusion or tamponade incidence between the two branches. 

4_philippe_meurin
Philippe Meurin
2014-08-31

Original title: Colchicine for Post- operative Pericardial Effusion: The post-operative pericardial effusion (POPE-2) Study. A multicenter, double-blind, randomized trial.

More articles by this author

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks...

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...